9 results about "Succinate dehydrogenase" patented technology

The invention belongs to the technical field of gene engineering, and discloses identification of strawberry powdery mildew succinate dehydrogenase related gene SDHB nucleotide point mutation and application of the strawberry powdery mildew succinate dehydrogenase related gene SDHB nucleotide point mutation in SDHI bactericide resistance monitoring. The invention specifically discloses a molecular detection method for identifying the drug resistance of the base mutation of the strawberry powdery mildew SDHB gene to SDHI bactericides and a special primer thereof. The molecular detection method provided by the invention is high in sensitivity, good in stability and short in detection period, and can be used for monitoring the resistance gene frequency of strawberry powdery mildew to SDHI fungicides and the occurrence and development conditions of resistance in a high-throughput manner.

This invention belongs to the field of biomedical technology, specifically relating to compounds for treating KRAS-mutant tumors and their uses. This invention provides compound 666-15, which provides dual inhibition of cytoplasmic-mitochondrial NAD5. + Transport (via targeting SLC25A51) and succinate dehydrogenase (SDH / complex II), while simultaneously disrupting mitochondrial NAD. + Transport and respiratory chain NAD + A novel therapeutic strategy to target KRAS-mutant tumors by utilizing regenerative functions.

The present application provides a kind of derivative of dual-target inhibitor structure, the compound has the structure of formula (I) as shown in formula (I): formula (I) wherein, in formula (I) R1 It is selected from phenyl, 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 4-chlorophenyl, 4-bromophenyl, 4-trifluoromethylphenyl, 4-methylphenyl, 4-ethylphenyl, 4-isopropylphenyl, 4-methoxyphenyl, 4-nitrophenyl, 4-methylsulfonylphenyl, thienyl, pyridyl, 3,5-difluorophenyl, 3,5-dichlorophenyl, 3,4,5-trifluorophenyl;R2 It is selected from H, halogen, trifluoromethyl, R2 It is in arbitrary position substitution position, single substitution or multiple substitution.The present application uses the derivative of the dual-target inhibitor structure for the use of the agent for preventing and treating plant pathogenic fungi.It can be seen that it has inhibitory effect on various plant fungi, and the inhibitory effect in sclerotinia is more significant.It has significant inhibitory effect on succinate dehydrogenase and chitin synthase activity.

The present invention relates to a synergistically effective fungicidal composition comprising, as component (A), a fungicidally active amount of choline phosphonate and, as component (B), at least one additional fungicide selected from the group comprising quinone fungicides, succinate dehydrogenase inhibitors, benzamide fungicides, sulfur fungicides, carboxylic acid amide fungicides, demethylation inhibitor fungicides, phenylamide fungicides, copper fungicides, piperidinyl thiazol isoxazoline fungicides, and sugar alcohols, wherein the weight ratio of components (A) and (B) is in the range of 1:1000 to 1000:1. The invention further relates to a kit for using the fungicidal composition according to the invention in an amount effective for controlling one or more types of fungal infections by applying the fungicidal composition to the fungal infections.

The present disclosure relates to fungicidal combinations, compositions including the fungicidal combinations, and to a method of controlling fungal diseases using the combinations. The combination includes at least one demethylation inhibitor; at least one succinate dehydrogenase (SDH) inhibitor; at least one RNA polymerase I inhibitor; and at least one ß-tubulin assembly inhibitor and / or at least one multi-site fungicide.

The evidences provided by the present patent application demonstrate the therapeutic effect of succinate dehydrogenase inhibition to counteract the cardiotoxicity of chemotherapies used in cancer, such as acute myeloid leukemia and breast cancer. This combination also remarkably exhibits a chemosensitizing capacity of cancer cells. The use of Malonate in patients affected by these pathologies would therefore protect the heart from the toxic side effects of chemotherapy and eliminate the most resistant cells for an ever better risk-benefit ratio for these patients. Accordingly, the present invention relates to a method for the treatment of chemotherapy-induced cardiotoxicity in a subject in need thereof comprising administering to said subject a therapeutically effective amount of a succinate dehydrogenase inhibitor.

A genetically engineered microorganism for producing succinate, including: a host cell derived from a methylotrophic bacterium. The host cell has an ethylmalonyl-CoA pathway. The activity of succinate dehydrogenase in the methylotrophic bacterium is reduced or inactivated, and the genetically engineered microorganism is capable of growing using methanol as the sole carbon source and producing succinate. Also provided herein are methods for producing succinate and methods for making genetically engineered microorganisms for producing succinate.

This invention aims to provide a method for preparing bis(4-pyrazolone)methane compounds. The preparation method is as follows: a mixture of compound A and compound B is added to an organic mixed solvent, heated under reflux at a certain temperature for 4-6 hours, then filtered while hot. The filtrate is allowed to evaporate the solvent naturally at room temperature to obtain the final target product C. R1, R2, R3, R4, and R5 are any one of alkyl, aryl, heterocyclic, or hydrogen atoms, respectively. The method for preparing bis(4-pyrazolone)methane compounds provided by this invention requires fewer raw materials, has simpler synthesis steps, milder reaction conditions, and higher yield than traditional methods. These compounds have the ability to improve the growth rate of edible fungi mycelia and activate the activity of mycelial succinate dehydrogenase, and can be used as potential growth regulators for edible fungi.

The invention relates to the field of diagnosis and treatment of skin injury caused by ultraviolet rays, in particular to succinate dehydrogenase (SDH) serving as a marker of the skin injury caused by the ultraviolet rays and application of the succinate dehydrogenase (SDH) to preparation of a treatment medicine. The activity of SDH in skin tissues and cells is remarkably reduced due to ultraviolet irradiation, so that macrophages are promoted to be polarized to M1 type, and inflammatory response is aggravated. The SDH activity is detected, so that the SDH can be used as an effective marker for diagnosing and monitoring skin injury caused by ultraviolet rays. Through overexpression of SDH subunit A or use of a TRAP1 inhibitor DN401, SDH activity can be recovered, macrophage M1 polarization can be inhibited, and skin erythema, edema and the like caused by ultraviolet rays can be significantly relieved. The invention provides a new diagnosis and treatment strategy, effectively prevents and treats skin injury caused by ultraviolet rays by intervening SDH activity, and has a remarkable clinical application prospect.